ArticleResearch in pharmaceutical sciences2026
Pinostrobin pentanoate as a selective estrogen receptor-
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related death among women worldwide. Estrogen receptor alpha (ERα) plays a major role in breast cancer cell proliferation, and approximately 70-80% of breast cancer cases are classified as Erα-positive. This study aims to predict the pinostrobin pentanoate potential against ERα by docking and molecular dynamics, and determine its cytotoxic activity against T47D breast cancer cells and normal cells. Experimental approach: Docking was analyzed using MOE 2022.02. Furthermore, AMBER 20 was used for molecular dynamics. Cytotoxicity was assessed using the MTT assay against T47D breast cancer cells and Vero cells for its selectivity index (SI). Findings/Results: Based on docking results, the binding free energy of pinostrobin pentanoate (-7.682 ± 0.145 kcal/mol) was lower compared to pinostrobin (-6.503 ± 0.153 kcal/mol) against ERα, indicating the stronger binding affinity. In addition, the stability interaction using 100 ns molecular dynamics showed a stable interaction. Moreover, the IC Conclusion and implications: Pinostrobin pentanoate is more selective than pinostrobin, and it can be used as an anti-breast cancer candidate against the ERα for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.